Menu

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

Learn about treatment options, treatment failure, associated adverse effects and more.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Setting Susceptibility Breakpoints: A Look Behind the Curtain

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.
A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 
 View more SIDPEC Activities
 

NOTE: If you attended this live CE activity that was held on November 14, 2020 at the SIDP Annual Meeting AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-20-519-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.

Description

Susceptibility breakpoints and a review of setting, revising and assessing their values will be discussed. Examining data sources, different approaches, and indicators for reassessment will offer key points of insight in this activity.

This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.

Learning Objectives

The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:

  • Describe the data sources used to establish or reassess susceptibility breakpoints.
  • Discuss the advantages and disadvantages of different approaches for setting susceptibility breakpoints, including epidemiological cutoff values and PK-PD- and clinical-based approaches.
  • Discuss the indicators suggesting the need to reassess susceptibility breakpoints.

Faculty

Sujata M. Bhavnani, Pharm.D., M.S., FIDSA
Institute for Clinical Pharmacodynamics, Inc.
Schenectady, New York

Accreditation

Release Date: November 14, 2020
Expiration Date: November 14, 2023

Pharmacists

ACPE LogoThis activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-519-H01-P has been assigned to this home-study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. Bhavnani has disclosed the following: Employer: Employed by and have equity in ICPD, a company that provides pharmacometric services to industry. Financial Interests or Benefits: Amplyx Pharmaceuticals, Inc., AN2, Antabio, Arixa Pharmaceuticals, Arsanis Inc., Basilea Pharmaceutica, B. Braun Medical Inc., BLC USA, Boston Pharmaceuticals, Cidara Therapeutics Inc., Cipla, USA, Cumberland Pharmaceuticals, Debiopharm International SA, Discuva Limited, E-Scape Bio, Enhanced Pharmacodynamics, Entasis Therapeutics, Genentech, Geom Therapeutics, Inc., GlaxoSmithKline, Hoffmann-La Roche, Indalo Therapeutics, Insmed Inc., KBP Biosciences USA, Matinas, Meiji Seika Pharma Co., Ltd., Melinta Therapeutics, Menarini Ricerche S.p.A, Mutabilis, Nabriva Therapeutics AG, Naeja-RGM Pharmaceuticals, Novartis Pharmaceuticals Corp., NuCana Biomed, Paratek Pharmaceuticals, Inc., Polyphor, Ltd., PTC Therapeutics, Sagimet, Spero Therapeutics, TauRx Therapeutics, Tetraphase Pharmaceuticals, Theravance Biopharma Pharmaceutica, USCAST, VenatoRx, Wockhardt Bio AG, and Zogenix International. Has ownership interest in, and is a member of Bravos Biosciences, LLC and its wholly owned subsidiaries BB100, LLC (which is partially funded by Carb-X) and B200, LLC (which is currently unfunded), and ICPD Biosciences, LLC, which contributed to federally funded projects in support of Symbiotica, Inc.

Funding

No external support has been received for this activity.

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.